NIH Clinical Trial Integrity Act

HR 247 / S 46, Health Care Affordability Act; S 2420, No Surprises Act Enforcement Act; HR 3521, the Clinical Trial Modernization Act; HR 5526, Biosimilar Red Tape Elimination Act; HR 5582, S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9661, Expedited Access to Biosimilars Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 4509, Patients Before Monopolies Act; Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to the modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program;

Client expense: $590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Prohibiting copay accumulators in ACA Exchange plans: Help Ensure Lower Patient (HELP) Copays Act (H.R. 6423/S. 864); Prohibit use of Alternative Funding Programs in private insurance; Transparency and streamline utilization management protocols including prior authorization and step therapy, Safe Step Act, and Improving Senior's Timely Access to Care Act; Extend or make permanent Medicare telehealth flexibilities; Extend federal flexibilities for teleprescribing of controlled substances; Extend Affordable Care Act (ACA) Enhance Premium Tax Credits; Reduce barriers to participation in clinical trials (H.R. 3521, H.R. 4184) and increase participation of underrepresented groups (H.R. 6867/S.3564); Increase CMS outreach and education on the Medicare Prescription Payment Program, Increasing Medication Access for Seniors Act (H.R. 6401).

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE